Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma

NCT02972840 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02972840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02972840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
Lead sponsor
Acerta Pharma BV
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 5, 2017
Completion date
February 15, 2027
Enrollment
635 (actual)
Sites
228

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, mantle cell